0000000000456339

AUTHOR

S. Marcotullio

showing 3 related works from this author

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

2019

AbstractBackgroundAlcohol consumption is a known risk factor for liver disease in HIV-infected populations. Therefore, knowledge of alcohol consumption behaviour and risk of disease progression associated with hazardous drinking are important in the overall management of HIV disease. We aimed at assessing the usefulness of routine data collected on alcohol consumption in predicting risk of severe liver disease (SLD) among people living with HIV (PLWHIV) with or without hepatitis C infection seen for routine clinical care in Italy.MethodsWe included PLWHIV from two observational cohorts in Italy (ICONA and HepaICONA). Alcohol consumption was assessed by physician interview and categorized ac…

Male030508 substance abuseHIV InfectionsSeverity of Illness IndexCohort StudiesLiver disease0302 clinical medicineRisk FactorsEpidemiologyMedicineHIV InfectionAlcohol consumptionAlcohol consumption HIV-infected HIV/HCV co-infection Severe liver disease030212 general & internal medicineeducation.field_of_studyCoinfectionLiver Diseaselcsh:Public aspects of medicineLiver DiseasesHazard ratioHepatitis CMiddle AgedHepatitis CItalyalcohol consumption; HIV-infected; HIV/HCV co-infection; severe liver diseaseCoinfectionFemale0305 other medical scienceHumanCohort studyResearch ArticleAdultmedicine.medical_specialtyAlcohol DrinkingPopulationSevere liver diseaseHIV/HCV co-infectionNO03 medical and health sciencesEnvironmental healthHumansRisk factorAlcohol consumption; HIV-infected; HIV/HCV co-infection; Severe liver disease; Adult; Alcohol Drinking; Cohort Studies; Female; HIV Infections; Hepatitis C; Humans; Italy; Liver Diseases; Male; Middle Aged; Risk Factors; Severity of Illness Index; CoinfectioneducationHIV-infectedbusiness.industryRisk FactorPublic Health Environmental and Occupational Healthlcsh:RA1-1270medicine.diseaseCohort StudiebusinessBMC Public Health
researchProduct

Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2021

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included…

MaleHIV AIDSHIV Infections0302 clinical medicineInterquartile rangeRisk FactorsNeoplasmsMedicine030212 general & internal medicineProspective StudiesProspective cohort study0303 health sciencesIncidenceAbsolute risk reductionDrugsGeneral MedicineMiddle AgedViral LoadAntiretroviral therapy3. Good healthAIDSCancer treatmentPrevention policy and public healthCohortInfectious diseasesCohort studiesFemaleViral loadAdultmedicine.medical_specialtyAnti-HIV AgentsHIV Infections/drug therapySocio-culturaleTime-to-Treatment03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingInternal medicineInternal MedicineHumansAdverse effect030306 microbiologybusiness.industryHIVCancermedicine.diseaseCD4 Lymphocyte CountCancer.Anti-HIV Agents/therapeutic use[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessNeoplasms/epidemiologyAnnals of Internal Medicine
researchProduct

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

2018

Background The CD4/CD8 ratio has been associated with the risk of AIDS and non-AIDS events. We describe trends in immunological parameters in people who underwent a switch to monotherapy or dual therapy, compared to a control group remaining on triple antiretroviral therapy (ART). Methods We included patients in Icona who started a three-drug combination ART regimen from an ART-naïve status and achieved a viral load ≤ 50 copies/mL; they were subsequently switched to another triple or to a mono or double regimen. Standard linear regression at fixed points in time (12-24 months after the switch) and linear mixed model analysis with random intercepts and slopes were used to compare CD4 and CD8…

0301 basic medicineMaleCD4-CD8 Ratiolcsh:MedicineHIV InfectionsCD8-Positive T-LymphocytesCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir; Medicine (all)Cohort Studies0302 clinical medicineEmtricitabineHIV Infection030212 general & internal medicineMedicine (all)General MedicineChronic inflammationCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Medicine (all)Middle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaReverse Transcriptase InhibitorReverse Transcriptase InhibitorsFemalecd4/cd8 ratio; cd8; chronic inflammation; dual therapy; monotherapy; medicine (all)Research Articlemedicine.drugCohort studyHumanAdultmedicine.medical_specialtyDual therapyCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; TenofovirAnti-HIV Agents030106 microbiologyCD4-CD8 RatioEmtricitabineSettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesCD4/CD8 ratioInternal medicineLinear regressionmedicineHumansDual therapyTenofovirbusiness.industrylcsh:RAnti-HIV AgentCD8CD8-Positive T-LymphocyteMonotherapyConfidence intervalRegimenCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; MonotherapyCD8; CD4/CD8 ratio; Chronic inflammation; Monotherapy; Dual therapyCohort StudiebusinessCD8
researchProduct